Drug Discovery
By
Could Takeda’s Landmark Phase 3 Oveporexton Results Redefine the Standard of Care in Narcolepsy Type 1?
Key Highlights Clinical Breakthroughs Across EndpointsPatients treated with oveporexton demonstrated marked improvements in excessive daytime sleepiness, with most…
Could Roche’s New Vabysmo Data Redefine Long-Term Care in “wet” age-related macular degeneration (nAMD)?
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
Could Lilly’s Olomorasib Breakthrough Designation Reshape the First-Line Treatment Landscape in KRAS G12C-Mutant Lung Cancer?
Key Takeaways Regulatory Milestone Positions Lilly in the KRAS Race The U.S. FDA has granted Breakthrough Therapy designation…
Is Novartis’ $5.2B siRNA Expansion with Argo Biopharma the Next Big Move in Cardiovascular?
Key Takeaways Expanding RNAi Leadership in Cardiovascular and Metabolic Diseases Novartis is reinforcing its strategic focus on cardiovascular…
Could CagriSema Become the First Once-Weekly GLP-1 and Amylin Combination Approved by the FDA?
United States / Denmark Novo Nordisk has submitted a New Drug Application to the U.S. Food and Drug…
U.S. FDA Awards National Priority Review Vouchers to Merck for Cholesterol and Cancer Drug Candidates
United States — The U.S. Food and Drug Administration (FDA) has awarded Commissioner’s National Priority Review Vouchers to…
